Source:http://linkedlifedata.com/resource/pubmed/id/11001888
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2000-10-10
|
| pubmed:abstractText |
The safety and efficacy of administering ex vivo expanded peripheral blood progenitor cells (PBPC) to patients with breast cancer who undergo high-dose chemotherapy and PBPC transplantation was investigated. Unselected PBPC were cultured in gas-permeable bags containing 1-L serum-free media, granulocyte colony-stimulating factor, stem cell factor, and pegylated megakaryocyte growth and development factor for 9 days. Cell dose cohorts were assigned to have between 2 and 24 x 10(9) PBPC cultured at 1, 2, or 3 x 10(6) cells/mL. Twenty-four patients received high-dose chemotherapy followed by infusion of the cultured PBPC and at least 5 x 10(6) CD34(+) uncultured cryopreserved PBPC per kilogram. No toxicities resulted from infusions of the ex vivo expanded PBPC. The study patients had shorter times to neutrophil (P =.0001) and platelet (P =.01) recovery and fewer red cell transfusions (P =.02) than 48 historical controls who received the same conditioning regimen and posttransplantation care and at least 5 x 10(6) CD34(+) PBPC per kilogram. Improvements in all these endpoints were significantly correlated with the expanded cell dose. Nine of 24 (38%) patients recovered neutrophil counts above 500/microL by day 5 or 6 after transplantation, whereas none of the controls had neutrophil recovery before the eighth day. Seven (29%) patients had neutropenia for 3 or fewer days, and 9 (38%) patients did not experience neutropenic fevers or require broad-spectrum antibiotics. Therefore, ex vivo expanded PBPC are capable of ameliorating posttransplantation neutropenia, thrombocytopenia, and anemia in patients receiving high-dose chemotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
96
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2385-90
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11001888-Anemia,
pubmed-meshheading:11001888-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11001888-Breast Neoplasms,
pubmed-meshheading:11001888-Cell Count,
pubmed-meshheading:11001888-Cells, Cultured,
pubmed-meshheading:11001888-Culture Media, Serum-Free,
pubmed-meshheading:11001888-Flow Cytometry,
pubmed-meshheading:11001888-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11001888-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11001888-Hematopoietic Stem Cells,
pubmed-meshheading:11001888-Humans,
pubmed-meshheading:11001888-Immunophenotyping,
pubmed-meshheading:11001888-Length of Stay,
pubmed-meshheading:11001888-Neutropenia,
pubmed-meshheading:11001888-Platelet Transfusion,
pubmed-meshheading:11001888-Stem Cell Factor,
pubmed-meshheading:11001888-Thrombocytopenia,
pubmed-meshheading:11001888-Thrombopoietin
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer.
|
| pubmed:affiliation |
Departments of Medicine and Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA. paquette@ucla.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|